Breast MRI for Assessing Triple-Negative Breast Cancer after Neoadjuvant Chemoimmunotherapy.
作者信息
Onishi Natsuko
机构信息
Department of Radiology & Biomedical Imaging, University of California, San Francisco, 550 16th St, San Francisco, CA 94158.
出版信息
Radiology. 2025 Jul;316(1):e251503. doi: 10.1148/radiol.251503.
Abstract
摘要
相似文献
1
Breast MRI for Assessing Triple-Negative Breast Cancer after Neoadjuvant Chemoimmunotherapy.新辅助化疗免疫治疗后采用乳腺磁共振成像评估三阴性乳腺癌
Radiology. 2025 Jul;316(1):e251503. doi: 10.1148/radiol.251503.
2
Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis.新辅助化疗免疫治疗早期三阴性乳腺癌的病理完全缓解：一项更新的荟萃分析。
Cells. 2022 Jun 7;11(12):1857. doi: 10.3390/cells11121857.
3
Why combine and why neoadjuvant? Tumor immunological perspectives on chemoimmunotherapy in triple-negative breast cancer.为何联合以及为何采用新辅助治疗？三阴性乳腺癌化学免疫治疗的肿瘤免疫学观点。
Breast Cancer. 2025 May 6. doi: 10.1007/s12282-025-01707-5.
4
Baseline and Early Treatment MRI Model for Predicting Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy in Patients With Triple-Negative Breast Cancer.用于预测三阴性乳腺癌患者对新辅助化疗免疫疗法完全病理反应的基线和早期治疗MRI模型
AJR Am J Roentgenol. 2025 Jul 30. doi: 10.2214/AJR.25.33178.
5
Posttreatment MRI to Predict Pathologic Complete Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy.治疗后磁共振成像预测三阴性乳腺癌对新辅助化疗免疫治疗的病理完全缓解
Radiology. 2025 Jul;316(1):e243824. doi: 10.1148/radiol.243824.
6
Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis.新辅助化疗免疫治疗治疗三阴性乳腺癌的停药率和严重不良事件：系统评价和荟萃分析。
ESMO Open. 2023 Dec;8(6):102198. doi: 10.1016/j.esmoop.2023.102198. Epub 2023 Dec 14.
7
Diagnostic performance of MRI for assessing axillary lymph node status after neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.MRI 评估乳腺癌新辅助化疗后腋窝淋巴结状态的诊断性能：系统评价和荟萃分析。
Eur Radiol. 2024 Feb;34(2):930-942. doi: 10.1007/s00330-023-10155-8. Epub 2023 Aug 24.
8
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.新辅助帕博利珠单抗联合卡铂加多西他赛治疗三阴性乳腺癌的临床和生物标志物研究：NeoPACT Ⅱ期临床试验。
JAMA Oncol. 2024 Feb 1;10(2):227-235. doi: 10.1001/jamaoncol.2023.5033.
9
Correlation Between Pathological and MRI Radiological Tumor Responses to Neoadjuvant Chemotherapy in Non-Luminal Breast Cancer: A Single Institution Experience.非腔面型乳腺癌新辅助化疗后病理与MRI影像学肿瘤反应的相关性：单机构经验
Cancer Rep (Hoboken). 2025 Jul;8(7):e70275. doi: 10.1002/cnr2.70275.
10
Intratumoral microbiota-aided fusion radiomics model for predicting tumor response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer.用于预测三阴性乳腺癌新辅助化疗免疫治疗肿瘤反应的瘤内微生物群辅助融合放射组学模型
J Transl Med. 2025 Mar 20;23(1):352. doi: 10.1186/s12967-025-06369-7.
本文引用的文献
1
Posttreatment MRI to Predict Pathologic Complete Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy.治疗后磁共振成像预测三阴性乳腺癌对新辅助化疗免疫治疗的病理完全缓解
Radiology. 2025 Jul;316(1):e243824. doi: 10.1148/radiol.243824.
2
Emerging and Evolving Concepts in Cancer Immunotherapy Imaging.癌症免疫治疗影像学的新兴和发展概念。
Radiology. 2023 Jan;306(1):32-46. doi: 10.1148/radiol.210518. Epub 2022 Dec 6.
3
Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.新辅助全身治疗中极少数有显著缓解的浸润性乳腺癌患者免除乳房切除术：一项多中心、单臂、2 期临床试验。
Lancet Oncol. 2022 Dec;23(12):1517-1524. doi: 10.1016/S1470-2045(22)00613-1. Epub 2022 Oct 25.
4
MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis.MRI评估乳腺癌亚型新辅助化疗后的反应：一项系统评价和荟萃分析。
NPJ Breast Cancer. 2022 Sep 19;8(1):107. doi: 10.1038/s41523-022-00475-1.
5
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.新辅助化疗后残余肿瘤负担与乳腺癌长期生存结局：5161 例患者的多中心汇总分析。
Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11.
6
Personalization of Treatment is the Way Forward in Care and Trials.个体化治疗是未来医疗和临床试验的发展方向。
Clin Cancer Res. 2020 Jun 15;26(12):2771-2773. doi: 10.1158/1078-0432.CCR-20-0604. Epub 2020 Apr 7.
7
Pembrolizumab for Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌。
N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.
8
Imaging Neoadjuvant Therapy Response in Breast Cancer.乳腺癌新辅助治疗反应的影像学评估。
Radiology. 2017 Nov;285(2):358-375. doi: 10.1148/radiol.2017170180.
9
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.新辅助化疗后与残留癌负荷及乳腺癌亚型相关的长期预后风险
J Clin Oncol. 2017 Apr 1;35(10):1049-1060. doi: 10.1200/JCO.2015.63.1010. Epub 2017 Jan 30.
10
Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype.新辅助化疗期间乳腺癌的磁共振成像反应监测：乳腺癌亚型的相关性。
J Clin Oncol. 2011 Feb 20;29(6):660-6. doi: 10.1200/JCO.2010.31.1258. Epub 2011 Jan 10.
Zotero 插件